
310.ai is building a generative AI engine to make programmable biology a reality. Their core product, Molecule Programming (MP), is a foundational AI model that transforms protein function descriptions into sequences. This text-to-protein generation compresses billions of years of natural evolution to create novel proteins for applications in medicine, industry, and environmental engineering. The MP model has demonstrated significant success, including generating over 1,053 AI-designed proteins, achieving a 6,590 protein generation milestone with 100% enzyme class coverage, and a notable 84% lab expression rate, far exceeding traditional methods. They are focused on making biology more accessible and impactful for solving real-world problems.

310.ai is building a generative AI engine to make programmable biology a reality. Their core product, Molecule Programming (MP), is a foundational AI model that transforms protein function descriptions into sequences. This text-to-protein generation compresses billions of years of natural evolution to create novel proteins for applications in medicine, industry, and environmental engineering. The MP model has demonstrated significant success, including generating over 1,053 AI-designed proteins, achieving a 6,590 protein generation milestone with 100% enzyme class coverage, and a notable 84% lab expression rate, far exceeding traditional methods. They are focused on making biology more accessible and impactful for solving real-world problems.
What they do: Generative AI models for de novo protein and peptide design (text-to-protein)
Founded: 2022
Headquarters: San Francisco, United States
Notable lab results: Reported ~84% expression rate in a 96-protein test
Team size (approx.): 9 employees
De novo protein and peptide design using generative AI to compress evolutionary search and produce functional sequences.
2022
Biotechnology
Crunchbase lists Cota Capital as lead; investors include Cota Capital and AVV.
“Cota Capital led seed; investors include AVV”